NCT05533697 2026-04-03
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc.
Phase 1/2 Recruiting
Clinical Trials
12 trialsNCT04421560 2026-02-20
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT05084430 2026-01-22
Study of Pembrolizumab and M032 (NSC 733972)
University of Alabama at Birmingham
Phase 1/2 Recruiting
NCT03160079 2025-11-10
Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
University of California, San Diego
Phase 1/2 Completed
NCT04358237 2025-06-04
LUPER
Blanco, Dr Antonio Calles MD
Phase 1/2 Completed
NCT04815720 2025-01-08
KEYNOTE-B84
Vaccinex Inc.
Phase 1/2 Completed
NCT06016920 2024-12-17
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
Nykode Therapeutics ASA
Phase 1/2 Recruiting
NCT03257722 2024-02-28
PIL
Augusta University
Phase 1/2 Terminated
NCT05357898 2024-02-23
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ Biotechnologies
Phase 1/2 Terminated
NCT02963610 2021-12-30
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
Fox Chase Cancer Center
Phase 1/2 Terminated
NCT03873025 2021-08-17
PLACARD
University College, London
Phase 1/2 Withdrawn
NCT02289222 2019-11-05
1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
University of Maryland, Baltimore
Phase 1/2 Terminated